KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) EBITDA Margin (2016 - 2026)

Gsk has reported EBITDA Margin over the past 18 years, most recently at 30.06% for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 57.0% year-over-year to 30.06%; the TTM value through Mar 2026 reached 24.47%, up 597.0%, while the annual FY2025 figure was 24.28%, 1147.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 30.06% at Gsk, up from 12.76% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 31.89% in Q1 2022 and troughed at 2.36% in Q3 2024.
  • A 5-year average of 23.07% and a median of 23.92% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -2156bps in 2024 and later surged 2798bps in 2025.
  • Year by year, EBITDA Margin stood at 23.9% in 2022, then grew by 25bps to 29.89% in 2023, then crashed by -31bps to 20.57% in 2024, then tumbled by -38bps to 12.76% in 2025, then soared by 135bps to 30.06% in 2026.
  • Business Quant data shows EBITDA Margin for GSK at 30.06% in Q1 2026, 12.76% in Q4 2025, and 30.34% in Q3 2025.